Scilex Holding Company Common Stock

SCLXNASDAQUSD
5.65 USD
0.01 (0.18%)AT CLOSE (11:59 AM EDT)
5.70
0.05 (0.90%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
5.70
0.05 (0.90%)
🟢Market: OPEN

Scilex Holding Company Common Stock (SCLX) is currently trading at $5.70. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (145.4%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 25, 2026.

Open?$5.68
High?$5.88
Low?$5.56
Prev. Close?$5.66
Volume?20.9K
Avg. Volume?67.7K
VWAP?$5.75
Rel. Volume?0.31x
Bid / Ask
Bid?$4.40 × 100
Ask?$6.62 × 100
Spread?$2.22
Midpoint?$5.51
Valuation & Ratios
Market Cap?39.8M
Shares Out?8.5M
Float?6.3M
Float %?74.1%
P/E Ratio?N/A
P/B Ratio?-0.13
EPS?-$63.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Employees
34
Market Cap
39.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2022-11-11
Address
960 SAN ANTONIO ROAD
PALO ALTO, CA 94303
Phone: (650) 516-4310
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
18
Short Sent.?
63
Piotroski F-Score?1/9Weak
Altman Z-Score?-12.72Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.43%Low
Short Interest?152.6K
Days to Cover?4.0
Free Float6.3M
Avg Daily Volume38.6K
Settlement Date2026-08-14
Financial Health
Current Ratio?0.07Weak
Quick Ratio?0.06Weak
Cash Ratio?0.00Low
Debt/Equity?-0.27Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A
P/B?
S&P
97
-0.13CHEAP
P/S?
Peers
100
S&P
82
1.26CHEAP
P/FCF?
N/A
EV/EBITDA?
S&P
97
-0.4CHEAP
EV/Sales?
Peers
100
S&P
49
3.87FAIR
Returns & Efficiency
ROE?
Peers
50
S&P
97
145.4%STRONG
ROA?
S&P
3
-176.8%WEAK
Cash Flow & Enterprise
FCF?$-17811000
Enterprise Value?$122.3M
Fundamentals ratios updated end of day